296 related articles for article (PubMed ID: 33329725)
21. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
22. A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients.
Wu X; Lv D; Eftekhar M; Khan A; Cai C; Zhao Z; Gu D; Liu Y
Transl Androl Urol; 2020 Dec; 9(6):2572-2586. PubMed ID: 33457230
[TBL] [Abstract][Full Text] [Related]
23. Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery.
Li F; Ji JP; Xu Y; Liu RL
Clin Transl Oncol; 2019 Aug; 21(8):1067-1075. PubMed ID: 30637711
[TBL] [Abstract][Full Text] [Related]
24. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
Liu B; Li X; Li J; Jin H; Jia H; Ge X
Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
[TBL] [Abstract][Full Text] [Related]
25. The Development of a Gleason Score-Related Gene Signature for Predicting the Prognosis of Prostate Cancer.
Yimamu Y; Yang X; Chen J; Luo C; Xiao W; Guan H; Wang D
J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498737
[TBL] [Abstract][Full Text] [Related]
26. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer.
Shao N; Tang H; Mi Y; Zhu Y; Wan F; Ye D
Oncoimmunology; 2020 Jun; 9(1):1762473. PubMed ID: 32923125
[TBL] [Abstract][Full Text] [Related]
27. Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer.
Yang C; Chen L; Niu Q; Ge Q; Zhang J; Tao J; Zhou J; Liang C
Cancer Cell Int; 2022 Dec; 22(1):382. PubMed ID: 36471446
[TBL] [Abstract][Full Text] [Related]
28. Identification of a Five-Gene Signature and Establishment of a Prognostic Nomogram to Predict Progression-Free Interval of Papillary Thyroid Carcinoma.
Wu M; Yuan H; Li X; Liao Q; Liu Z
Front Endocrinol (Lausanne); 2019; 10():790. PubMed ID: 31803141
[No Abstract] [Full Text] [Related]
29. Identification of a nomogram based on long non-coding RNA to improve prognosis prediction of esophageal squamous cell carcinoma.
Li W; Liu J; Zhao H
Aging (Albany NY); 2020 Jan; 12(2):1512-1526. PubMed ID: 31978896
[TBL] [Abstract][Full Text] [Related]
30. A Novel Angiogenesis-Related Gene Signature to Predict Biochemical Recurrence of Patients with Prostate Cancer following Radical Therapy.
Fan B; Wang Y; Zheng X; Zhang X; Zhang Z; Hu X
J Oncol; 2022; 2022():2448428. PubMed ID: 35799610
[TBL] [Abstract][Full Text] [Related]
31. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
32. A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
Li X; Huang H; Zhang J; Jiang F; Guo Y; Shi Y; Guo Z; Ao L
Prostate; 2020 Apr; 80(5):376-387. PubMed ID: 31961962
[TBL] [Abstract][Full Text] [Related]
33. An anoikis-related gene signature for prediction of the prognosis in prostate cancer.
Zhao X; Wang Z; Tang Z; Hu J; Zhou Y; Ge J; Dong J; Xu S
Front Oncol; 2023; 13():1169425. PubMed ID: 37664042
[TBL] [Abstract][Full Text] [Related]
34. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
35. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
Li X; Zhang W; Song J; Zhang X; Ran L; He Y
Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
[TBL] [Abstract][Full Text] [Related]
36. An Integrated Model Based on a Six-Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma.
Li W; Lu J; Ma Z; Zhao J; Liu J
Front Genet; 2019; 10():1323. PubMed ID: 32010188
[No Abstract] [Full Text] [Related]
37. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
[TBL] [Abstract][Full Text] [Related]
38. Preoperative Predictors of Biochemical Recurrence-Free Survival in High-Risk Prostate Cancer Following Radical Prostatectomy.
Nkengurutse G; Tian F; Jiang S; Wang Q; Wang Y; Sun W
Front Oncol; 2020; 10():1761. PubMed ID: 33014867
[No Abstract] [Full Text] [Related]
39. SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy.
Li F; Xu Y; Liu RL
Int Urol Nephrol; 2019 Mar; 51(3):443-451. PubMed ID: 30739268
[TBL] [Abstract][Full Text] [Related]
40.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
